Genelux’s (GNLX) “Buy” Rating Reiterated at HC Wainwright

Genelux (NASDAQ:GNLX)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $30.00 price target on the stock.

Genelux Stock Performance

Shares of NASDAQ GNLX opened at $3.08 on Monday. The company has a market capitalization of $106.38 million, a PE ratio of -3.24 and a beta of -1.41. The company’s fifty day moving average price is $4.06 and its 200 day moving average price is $3.10. Genelux has a 1 year low of $1.60 and a 1 year high of $6.50.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09). On average, equities analysts expect that Genelux will post -0.88 EPS for the current year.

Institutional Investors Weigh In On Genelux

Several institutional investors and hedge funds have recently added to or reduced their stakes in GNLX. Geode Capital Management LLC grew its position in shares of Genelux by 39.7% in the third quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock valued at $749,000 after purchasing an additional 89,854 shares during the period. Marshall Wace LLP boosted its holdings in Genelux by 51.4% in the 4th quarter. Marshall Wace LLP now owns 156,058 shares of the company’s stock worth $368,000 after buying an additional 52,958 shares during the last quarter. LPL Financial LLC increased its stake in Genelux by 72.3% during the 4th quarter. LPL Financial LLC now owns 94,144 shares of the company’s stock worth $222,000 after buying an additional 39,516 shares in the last quarter. LifeSteps Financial Inc. raised its holdings in shares of Genelux by 11.1% during the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock valued at $205,000 after acquiring an additional 8,715 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Genelux in the third quarter worth about $59,000. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.